Form 4: Repligen Executive Receives Stock Grant
Insider Transaction (Form 4)
Brian Robb Douglass, CHIEF PRODUCT OFFICER of Repligen Corp, reported multiple transactions in common stock on October 6, 2026.
Summary
- Grant/award: acquired 700 Common Stock on October 6, 2026; holds 8,685 after (Direct).
- Grant/award: acquired 675 Stock Option (Right to Buy) on October 6, 2026; holds 675 after (Direct).
Sentiment
Score: 5
Explanation: StockSavvy.ai views this as routine: the reported changes are grants, option exercises, tax withholding or similar administrative transactions, which carry limited directional signal.
Insider Transactions
Brian Robb Douglass — Officer (CHIEF PRODUCT OFFICER)
| Date | Transaction | Security | Shares | Price | Value | Held After |
|---|---|---|---|---|---|---|
| 2026-10-06 | Grant/award | Common Stock | 700 | — | — | 8,685 |
| 2026-10-06 | Grant/award | Stock Option (Right to Buy) | 675 | — | — | 675 |
Key Dates
| Date | Description |
|---|---|
| 2026-10-06 | Grant/award (700 shares) |
| 2026-10-06 | Grant/award (675 shares) |
Keywords
insider transaction, Form 4, RGEN, REPLIGEN CORP, neutral, Brian Robb Douglass
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.